ARTICLE | Market Access
Tecvayli approval sets up modality competition in multiple myeloma
EC grants conditional marketing authorization to J&J’s first-in-class CD3 x BCMA bispecific
August 24, 2022 11:06 PM UTC
The EC’s approval of Tecvayli brings multiple myeloma patients a third modality against BCMA while strengthening J&J’s leadership position in the indication.
The launch of Tecvayli teclistamab — the first T cell engaging bispecific antibody to reach the European or U.S. markets since the 2016 approval of Blincyto blinatumomab from Amgen Inc. (NASDAQ:AMGN) — should also be an indicator of where the modality will fit into the therapeutic landscape to the more than 200 other companies developing bispecific T cell engagers. ...